Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease

Open access
HINDORF, U., LINDQVIST, M., HILDEBRAND, H., FAGERBERG, U., ALMER, S.·2006·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9–28% of patients with inflammatory bowel disease. Aims: To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse event. Methods: Three hundred and sixty‐four patients with inflammatory bowel disease and present or previous thiopurine therapy were identified from a local database. Results: The adverse event observed in 124 patients (34%) were more common in adults than children (40% vs. 15%; P < 0.001) and in low to intermediate (≤9.0 U/mL red blood cell) than normal thiopurine methyltransferase activity (P = 0.02). Myelotoxicity developed later than other types of adverse event. An increased frequency of adverse event was observed in patients with tioguanine (thioguanine) nucleotide above 400 or methylated thioinosine monophosphate above 11 450 pmol/8 × 10 8 red blood cell. A shift to mercaptopurine was successful in 48% of azathioprine‐intolerant patients and in all cases of azathioprine‐induced myalgia or arthralgia. Conclusions: A pre‐treatment determination of thiopurine methyltransferase status might be appropriate as patients with low to intermediate thiopurine methyltransferase activity are more prone to develop an adverse event; determination of metabolite levels can be useful in the case of an adverse event. Mercaptopurine therapy should be considered in azathioprine‐intolerant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2006.02977.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
HINDORF, U., LINDQVIST, M., HILDEBRAND, H., FAGERBERG, U., & ALMER, S.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2006-06-26
Volume
24
Issue
2
Pages
331-342
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2160237124
Cited by
168
References
1
FWCI
3.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02977.x
The paper
HINDORF, U., LINDQVIST, M., HILDEBRAND, H., FAGERBERG, U., & ALMER, S. (2006). Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02977.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.